Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations

Executive Summary

FDA and industry have finally struck a tentative deal that, with Congressional approval, aims to raise nearly a billion dollars over five years. It also holds FDA to higher quality metrics while starting a pilot project to use real-world evidence in tracking devices on the market.


Related Content

MDUFA IV Fees Unveiled: Changes For 510(k)s, Small Business, De Novos
Public Invited To Vet Draft User-Fee Agreement At Nov. 2 Meeting
Next Steps For NEST: Planning Board Lays Out Launch Strategy For Evaluation System
MDIC Snags $3m For FDA Real-World Evidence Coordinating Center
$30m In Device User Fees Will Go To Real-World Evidence Evaluation System
MDUFA IV Takes Shape: A Catalogue Of Draft Commitments
Final Guidance Encourages Use Of Patient Preference In Device Applications
FDA Moves Real-World Evidence Paradigm Forward With Draft Guidance
Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed
Too Soon To Say If US FDA Device Reforms Are Working, Says Independent Report